MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Werling, U.
Right arrow Articles by Göttlicher, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Werling, U.
Right arrow Articles by Göttlicher, M.

Vol. 59, Issue 5, 1269-1276, May 2001

Induction of Differentiation in F9 Cells and Activation of Peroxisome Proliferator-Activated Receptor delta  by Valproic Acid and Its Teratogenic Derivatives

Uwe Werling, Sandra Siehler, Margarethe Litfin, Heinz Nau, and Martin Göttlicher

Forschungszentrum Karlsruhe, Institute of Toxicology and Genetics, Eggenstein-Leopoldshafen, Germany (U.W., S.S., M.L., M.G.); and Zentrumsabteilung für Lebensmitteltoxikologie, der Tiermedizinischen Hochschule, Hannover, Germany (H.N.)

The antiepileptic drug valproic acid (VPA) is teratogenic, because it induces birth defects in some children of mothers treated for epilepsy. Cellular and molecular actions associated with teratogenicity were identified by testing differentiation of F9 embryocarcinoma cells. VPA altered cell morphology and delayed proliferation. Specific differentiation markers (e.g., c-fos and keratin 18 mRNA and particularly the activating protein-2 transcription factor protein) were induced. This pattern differs from the pattern induced by other teratogens or F9 cell-differentiating agents. Induction of differentiation correlated with teratogenicity because teratogenic derivatives of VPA, such as (S)-4-yn-VPA, induced differentiation, whereas closely related nonteratogenic compounds, such as (R)-4-yn-VPA, 2-en-VPA, and 4-methyl-VPA, did not. In the cellular signaling network, the peroxisome proliferator-activated receptor delta  (PPARdelta ) was activated selectively by VPA and teratogenic derivatives. Depletion of PPARdelta by antisense RNA expression precluded the response of F9 cells to VPA. In conclusion, our data show that VPA and its teratogenic derivatives induce a specific type of F9 cell differentiation and that PPARdelta is a limiting factor in the control of differentiation.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
P. Munster, D. Marchion, E. Bicaku, M. Lacevic, J. Kim, B. Centeno, A. Daud, A. Neuger, S. Minton, and D. Sullivan
Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
Clin. Cancer Res., April 1, 2009; 15(7): 2488 - 2496.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
W. Shan, P. S. Palkar, I. A. Murray, E. I. McDevitt, M. J. Kennett, B. H. Kang, H. C. Isom, G. H. Perdew, F. J. Gonzalez, and J. M. Peters
Ligand Activation of Peroxisome Proliferator-Activated Receptor {beta}/{delta} (PPAR{beta}/{delta}) Attenuates Carbon Tetrachloride Hepatotoxicity by Downregulating Proinflammatory Gene Expression
Toxicol. Sci., October 1, 2008; 105(2): 418 - 428.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. Cerveny, L. Svecova, E. Anzenbacherova, R. Vrzal, F. Staud, Z. Dvorak, J. Ulrichova, P. Anzenbacher, and P. Pavek
Valproic Acid Induces CYP3A4 and MDR1 Gene Expression by Activation of Constitutive Androstane Receptor and Pregnane X Receptor Pathways
Drug Metab. Dispos., July 1, 2007; 35(7): 1032 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Munster, D. Marchion, E. Bicaku, M. Schmitt, J. H. Lee, R. DeConti, G. Simon, M. Fishman, S. Minton, C. Garrett, et al.
Phase I Trial of Histone Deacetylase Inhibition by Valproic Acid Followed by the Topoisomerase II Inhibitor Epirubicin in Advanced Solid Tumors: A Clinical and Translational Study
J. Clin. Oncol., May 20, 2007; 25(15): 1979 - 1985.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Toxicol. Sci., April 1, 2006; 90(2): 269 - 295.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
X.-N. Li, Q. Shu, J. M.-F. Su, L. Perlaky, S. M. Blaney, and C. C. Lau
Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC
Mol. Cancer Ther., December 1, 2005; 4(12): 1912 - 1922.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Lampen, P. A. Grimaldi, and H. Nau
Modulation of Peroxisome Proliferator-Activated Receptor {delta} Activity Affects Neural Cell Adhesion Molecule and Polysialyltransferase ST8SiaIV Induction by Teratogenic Valproic Acid Analogs in F9 Cell Differentiation
Mol. Pharmacol., July 1, 2005; 68(1): 193 - 203.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. J. Kim, I. A. Murray, A. M. Burns, F. J. Gonzalez, G. H. Perdew, and J. M. Peters
Peroxisome Proliferator-activated Receptor-{beta}/{delta} Inhibits Epidermal Cell Proliferation by Down-regulation of Kinase Activity
J. Biol. Chem., March 11, 2005; 280(10): 9519 - 9527.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
J. R. Wood, V. L. Nelson-Degrave, E. Jansen, J. M. McAllister, S. Mosselman, and J. F. Strauss III
Valproate-induced alterations in human theca cell gene expression: clues to the association between valproate use and metabolic side effects
Physiol Genomics, February 10, 2005; 20(3): 233 - 243.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Kuendgen, C. Strupp, M. Aivado, A. Bernhardt, B. Hildebrandt, R. Haas, U. Germing, and N. Gattermann
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid
Blood, September 1, 2004; 104(5): 1266 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. L. Stephen, M. C. U. Gustafsson, M. Jarvis, R. Tatoud, B. R. Marshall, D. Knight, E. Ehrenborg, A. L. Harris, C. R. Wolf, and C. N. A. Palmer
Activation of Peroxisome Proliferator-Activated Receptor {delta} Stimulates the Proliferation of Human Breast and Prostate Cancer Cell Lines
Cancer Res., May 1, 2004; 64(9): 3162 - 3170.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Michaelis, U. R. Michaelis, I. Fleming, T. Suhan, J. Cinatl, R. A. Blaheta, K. Hoffmann, R. Kotchetkov, R. Busse, H. Nau, et al.
Valproic Acid Inhibits Angiogenesis in Vitro and in Vivo
Mol. Pharmacol., March 1, 2004; 65(3): 520 - 527.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. J. Arinze and Y. Kawai
Sp Family of Transcription Factors Is Involved in Valproic Acid-induced Expression of Galpha i2
J. Biol. Chem., May 9, 2003; 278(20): 17785 - 17791.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. J. Bauerschmitz, D. M. Nettelbeck, A. Kanerva, A. H. Baker, A. Hemminki, P. N. Reynolds, and D. T. Curiel
The flt-1 Promoter for Transcriptional Targeting of Teratocarcinoma
Cancer Res., March 1, 2002; 62(5): 1271 - 1274.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics